Join to View Full Profile
1050 Brickell AveUnit 3018Miami, FL 33131
Phone+1 818-574-3062
Dr. Lakhan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Shaheen Lakhan, MD, PhD, is a board-certified neurologist and pain medicine specialist, physician-scientist, and biotechnology executive. Trained at Cleveland Clinic and Massachusetts General Hospital, he has over two decades of experience across clinical care, academia, and industry.
A former department chair and medical school dean, he is currently a professor of neurology and has authored over 100 peer-reviewed publications, earning numerous honors, including recognition from the U.S. Congress and presidential and gubernatorial appointments to advisory boards.
He is Board Director and former Chief Medical and Scientific Officer of leading biotechs. He has built and led clinical programs, residency training programs, and the development of novel medicines. His clinical focus includes neurology, psychiatry, and pain.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Pain Medicine, 2014 - 2015
Cleveland Clinic FoundationResidency, Internal Medicine, 2010 - 2014- Cleveland Clinic FoundationResidency, Neurology, 2010 - 2014
Technion-Israel Inst of Technology Faculty of MedicineClass of 2009, MD, Cum Laude
Certifications & Licensure
FL State Medical License 2021 - 2028
MI State Medical License 2022 - 2028
CO State Medical License 2022 - 2027
TX State Medical License 2022 - 2027
TN State Medical License 2024 - 2027
KY State Medical License 2024 - 2027
MA State Medical License 2014 - 2027
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Pain Medicine
- Join now to see all
Clinical Trials
- The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine Start of enrollment: 2012 Jul 01
- A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia Start of enrollment: 2019 Feb 04
- A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) Start of enrollment: 2022 Sep 30
Publications & Presentations
PubMed
- 5 citationsA digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study).Brian Rothman, Mary Slomkowski, Austin Speier, A John Rush, Madhukar H Trivedi
Journal of Affective Disorders. 2025-11-01 - 1 citationsEffectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase ...Shaheen E Lakhan, Cornelia Dorner-Ciossek, Olya Besedina, Faith Dickerson, Claudia Hastedt
JMIR Research Protocols. 2025-10-07 - 1 citationsSoftware-Enhanced Drugs™: The third platform reshaping drug development.Shaheen E Lakhan, Paul Wicks
Proceedings of the National Academy of Sciences of the United States of America. 2025-09-30
Press Mentions
Agetech Research Round-up: Brain Health Vital, £38m to Combat Alzheimers, and More…January 14th, 2026- Oral Health a Neglected Stroke Risk Factor?October 27th, 2025
- Tear down the Wall Between Neurology and PsychiatryOctober 23rd, 2025
Professional Memberships
- Fellow
- International Association for the Study of Pain - IASPMember
- Member
- Member
Other Languages
- Hebrew, Spanish
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
